These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

293 related items for PubMed ID: 14744949

  • 1. Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites.
    Wang YH, Jones DR, Hall SD.
    Drug Metab Dispos; 2004 Feb; 32(2):259-66. PubMed ID: 14744949
    [Abstract] [Full Text] [Related]

  • 2. Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil.
    Wang YH, Jones DR, Hall SD.
    Drug Metab Dispos; 2005 May; 33(5):664-71. PubMed ID: 15689501
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. The effect of short- and long-term administration of verapamil on the disposition of cytochrome P450 3A and P-glycoprotein substrates.
    Lemma GL, Wang Z, Hamman MA, Zaheer NA, Gorski JC, Hall SD.
    Clin Pharmacol Ther; 2006 Mar; 79(3):218-30. PubMed ID: 16513446
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Inhibitory effects of verapamil and diltiazem on simvastatin metabolism in human liver microsomes.
    Yeo KR, Yeo WW.
    Br J Clin Pharmacol; 2001 May; 51(5):461-70. PubMed ID: 11422004
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Lack of correlation between in vitro inhibition of CYP3A-mediated metabolism by a PPAR-gamma agonist and its effect on the clinical pharmacokinetics of midazolam, an in vivo probe of CYP3A activity.
    Fayer JL, Zannikos PN, Stevens JC, Luo Y, Sidhu R, Kirkesseli S.
    J Clin Pharmacol; 2001 Mar; 41(3):305-16. PubMed ID: 11269571
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Diltiazem inhibition of cytochrome P-450 3A activity is due to metabolite intermediate complex formation.
    Jones DR, Gorski JC, Hamman MA, Mayhew BS, Rider S, Hall SD.
    J Pharmacol Exp Ther; 1999 Sep; 290(3):1116-25. PubMed ID: 10454485
    [Abstract] [Full Text] [Related]

  • 19. Pharmacokinetic interaction between oral lovastatin and verapamil in healthy subjects: role of P-glycoprotein inhibition by lovastatin.
    Choi DH, Chung JH, Choi JS.
    Eur J Clin Pharmacol; 2010 Mar; 66(3):285-90. PubMed ID: 20012601
    [Abstract] [Full Text] [Related]

  • 20. Effects of oral epigallocatechin gallate on the oral pharmacokinetics of verapamil in rats.
    Chung JH, Choi DH, Choi JS.
    Biopharm Drug Dispos; 2009 Mar; 30(2):90-3. PubMed ID: 19226653
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.